IFG Advisory LLC increased its stake in shares of Chemed Corporation (NYSE:CHE – Free Report) by 92.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,808 shares of the company’s stock after purchasing an additional 3,274 shares during the quarter. IFG Advisory LLC owned 0.05% of Chemed worth $3,439,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Chemed in the 2nd quarter valued at about $691,290,000. First Trust Advisors LP boosted its stake in shares of Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock valued at $89,295,000 after buying an additional 46,791 shares during the period. Copeland Capital Management LLC grew its position in shares of Chemed by 1.3% during the third quarter. Copeland Capital Management LLC now owns 146,833 shares of the company’s stock worth $74,162,000 after buying an additional 1,826 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Chemed during the second quarter worth about $48,255,000. Finally, Caisse de depot et placement du Quebec acquired a new position in shares of Chemed during the second quarter worth about $44,309,000. Hedge funds and other institutional investors own 95.85% of the company’s stock.
Chemed Stock Up 0.2%
Chemed stock opened at $549.36 on Monday. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $562.24. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.11 and a quick ratio of 1.08. The stock has a market cap of $7.15 billion, a PE ratio of 26.28, a P/E/G ratio of 2.08 and a beta of 0.50. The stock’s fifty day moving average is $516.95 and its two-hundred day moving average is $467.59.
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.44 by $0.31. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The business had revenue of $690.94 million during the quarter, compared to analysts’ expectations of $685.04 million. During the same period in the prior year, the firm posted $5.27 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts expect that Chemed Corporation will post 24.05 EPS for the current fiscal year.
Chemed Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 4th. Investors of record on Monday, November 16th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Monday, November 16th. Chemed’s dividend payout ratio is 13.40%.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the stock. Royal Bank Of Canada raised their target price on shares of Chemed from $548.00 to $585.00 and gave the company a “sector perform” rating in a report on Thursday, October 29th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and lifted their price target for the stock from $520.00 to $620.00 in a research note on Wednesday, October 28th. Oppenheimer boosted their price target on shares of Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Bank of America reissued a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Chemed has a consensus rating of “Hold” and a consensus target price of $603.00.
Read Our Latest Research Report on Chemed
Insider Buying and Selling
In other Chemed news, EVP Spencer Lee sold 1,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $541.04, for a total value of $541,040.00. Following the transaction, the executive vice president directly owned 13,912 shares in the company, valued at $7,526,948.48. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin McNamara sold 2,000 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $537.90, for a total transaction of $1,075,800.00. Following the completion of the transaction, the chief executive officer owned 82,220 shares in the company, valued at $44,226,138. This represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 10,920 shares of company stock valued at $5,770,666 over the last ninety days. 3.33% of the stock is currently owned by corporate insiders.
About Chemed
Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services. VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.
Featured Articles
- Five stocks we like better than Chemed
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
